Benzylamide Derivatives for Tissue-Selective TGFβRI/ALK5 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with chronic overexpression of TGF-β, such as cancer and fibrosis, face challenges including toxicity and adverse effects from systemic inhibition of TGF-β signaling, particularly affecting heart valves and cardiovascular systems.
Innovation Solution
Development of benzylamide derivatives that act as potent inhibitors of TGFβRI/ALK5 with low systemic exposure, minimizing side effects by forming inactive metabolites, thereby targeting TGF-β signaling pathways in specific tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic inhibition of TGF-β signaling is used to treat diseases, then therapeutic effect is achieved, but toxicity and adverse effects on heart valves and cardiovascular system occur
Solution Approach 1:
The patent applies local quality by designing compounds with tissue-specific pharmacokinetic properties. The benzylamide derivatives exhibit low systemic exposure and rapid metabolism, creating a situation where the drug concentration is high enough to inhibit TGF-β signaling in target tissues (liver, skin, gastrointestinal tract) but low enough in the bloodstream to avoid cardiotoxicity. This spatial and temporal differentiation of drug concentration resolves the contradiction between achieving therapeutic effect and avoiding systemic toxicity.
Solution Approach 2:
The patent employs partial action by utilizing the brief window of high drug concentration immediately after administration. The compounds are designed to exert their maximum inhibitory effect during this short period when tissue concentrations are highest, then rapidly metabolize to inactive forms. This allows sufficient TGF-β inhibition in target organs without prolonged exposure that would cause cardiovascular damage, thus resolving the contradiction through time-limited therapeutic action.
2Reliability
If TGF-β signaling is inhibited to treat fibrotic conditions, then fibrosis is reduced, but cardiovascular side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the pharmacokinetic parameters of TGF-β inhibitors. The benzylamide derivatives are designed with specific metabolic parameters (rapid clearance, short half-life, low systemic exposure) that differ from conventional inhibitors. This parameter optimization allows the drug to achieve sufficient tissue penetration for anti-fibrotic effect while maintaining plasma concentrations below the threshold for cardiovascular toxicity, thus resolving the contradiction between efficacy and safety.
3Reliability
If potent TGFβRI/ALK5 inhibitors are developed, then therapeutic efficacy increases, but systemic exposure and metabolism stability create toxicity risks
Solution Approach 1:
The patent converts the potential harm of metabolic stability into a benefit by designing compounds that are deliberately unstable in systemic circulation. The benzylamide derivatives are engineered to be rapidly metabolized by hepatic enzymes into inactive metabolites, which are then excreted. This controlled metabolic instability prevents accumulation and systemic toxicity while maintaining sufficient drug levels at the site of action, thus resolving the contradiction between potency and safety through controlled degradation.
Data Source
AI summary
The present invention relates to novel benzylamide derivatives of formula (I)to processes for the preparation of said compounds; to pharmaceutical compositions comprising said compounds and to said compounds for use in the treatment of pathological conditions or diseases that can improve by inhibition of transforming growth factor-β receptor I (TGFβRI)/ALK5, such as diseases and disorders associated to fibrotic conditions of gastrointestinal system, skin and eyes, to methods for the treatment and/or prevention of said diseases or pathological conditions and to combinations comprising said compounds and further comprising therapeutically effective amounts of other therapeutic agents useful for the treatment of said diseases or pathological conditions.